# Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma

> **NCT01175980** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 30 (actual)

## Conditions studied

- Recurrent Oral Cavity Adenoid Cystic Carcinoma
- Recurrent Salivary Gland Carcinoma
- Salivary Gland Adenoid Cystic Carcinoma
- Stage III Major Salivary Gland Cancer AJCC v7
- Stage III Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
- Stage IVA Major Salivary Gland Cancer AJCC v7
- Stage IVA Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
- Stage IVB Major Salivary Gland Cancer AJCC v7
- Stage IVB Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
- Stage IVC Major Salivary Gland Cancer AJCC v7
- Stage IVC Oral Cavity Adenoid Cystic Carcinoma AJCC v6 and v7
- Tongue Carcinoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT01175980
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-08-06
- **Primary completion:** 2018-06-08
- **Final completion:** 2018-08-01
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2020-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01175980

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01175980, "Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01175980. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*